Cluster of SARS-CoV-2 Gamma Variant Infections,Parintins, Brazil,March 2021

High case counts after the Gamma (P. 1) variant of severe acute respiratory syndrome coronavirus 2 emerged in Brazil raised concerns that previously infected persons might become reinfected. Investigation of a cluster of coronavirus disease cases in Parintins, in the Brazilian Amazon, suggested household transmission but did not identify high rates of reinfection.     

2006年3月份全国甲乙类传染病疫情动态简介

病名Disease死亡数Death number本月Mar.去年同月Last Mar.本年累计Cum2006本月Mar.去年同月Last Mar.本年累计Cum2006去年累计Cum2005鼠疫Plague-------霍乱Cholera-------传染性非曲型肺炎SARS-------艾滋病AIDS 590 340 1 350 81 93 176 187肝炎Viral Hepatitis 140 816 118 476 347 824 109 134 286 292甲肝Type A 6 336 6 935 15 170 3 5 11 9乙肝Type B 116 831 96 866 291 642 76 103 211 224丙肝Type C 7 073 5 072 16 814 14 6 24 20戊肝Type E 2 677 2 159 5 913 8 12 13 15未分型Unspecified 7 899 7 444 18 285 8 …     

2007年1月份中国甲乙丙类传染病疫情动态简介

病名Disease死亡数(1)Death number本月Jan.去年同月Last Jan.本年累计Cum2007本月Jan.去年同月Last Jan.本年累计Cum2007去年累计Cum2006鼠疫Plague-------霍乱Cholera-------传染性非典型肺炎SARS-------艾滋病AIDS46638146635463546肝炎Viral Hepatitis12855795235128557939     

2007年4月份中国甲乙丙类传染病疫情动态简介

病名Disease死亡数(1)Death number本月Apr.去年同月Last Apr.本年累计Cum2007本月Apr.去年同月Last Apr.本年累计Cum2007去年累计Cum2006鼠疫Plague-------霍乱Cholera-------传染性非典型肺炎SARS-------艾滋病AIDS749773249192107313343肝炎Viral Hepatitis13922712707050903392140369462甲型Type A625756952225424415乙型Type B1149591061444233647698286336丙型Type C859863993063310183742戊型Type E2300237087083101425未分型Unspecified71136462240741102844脊髓灰质炎Poliomyelitis-------人感染高致病性禽流感HPAI…     

2007年8月份中国甲乙丙类传染病疫情动态简介

病名DiseaseDeath number本月Aug.去年同月Last Aug.本年累计Cum2007本月Aug.去年同月Last Aug.本年累计Cum2007去年累计Cum2006鼠疫Plague-------霍乱Cholera-------传染性非典型肺炎SARS-------艾滋病AIDS139148685112241115972肝炎Viral Hepatitis3164427894112056918297691     

2009年5月中国部分法定传染病疫情动态摘抄

流行性腮腺炎 天津市：2009年5月全市报告病例417例,与上月相比上升21．93％,与2008年同期相比下降47．28％。1-5月累计报告病例1185例,较2008年同期下降53．38％。全市18个区、县均有病例发生,报告发病数较多的地区为塘沽区84例、静海县68例、津南区63例。男性病例266例,女性151例。0～9岁年龄组病例250例,占全部病例的59．95％,10—19岁年龄组病例136例,占32．61％。学生病例最多,为279例,占全部病例的66．91％,其次为散居和幼托儿童106例,占25．42％。     

2009年12月中国部分法定传染病疫情动态摘抄

江苏省：2009年12月7—13日,全省共报告甲型H1N1流感确诊病例578例,较上周上升3．21％,报告死亡8例,南京市及徐州市各2例,无锡市、常州市、连云港市及镇江市各1例。病例报告地区主要有南京市（103例）、苏州市（96例）及扬州市（67例）。报告病例中男性299例、女性279例,男女性别比为1．07：1;     

Cost-effectiveness of intensive glycemic control,intensified hypertension control,and serum cholesterol level reduction for type 2 diabetes

Context  Several treatment interventions can reduce complications of type 2 diabetes, but their relative cost-effectiveness is not known. Objective  To estimate the incremental cost-effectiveness of intensive glycemic control (relative to conventional control), intensified hypertension control, and reduction in serum cholesterol level for patients with type 2 diabetes. Design, Setting, and Patients  Cost-effectiveness analysis of a hypothetical cohort of individuals living in the United States, aged 25 years or older, who were newly diagnosed as having type 2 diabetes. The results of the United Kingdom Prospective Diabetes Study (UKPDS) and other studies were used to create a model of disease progression and treatment patterns. Costs were based on those used in community practices in the United States. Interventions  Insulin or sulfonylurea therapy for intensive glycemic control; angiotensin-converting enzyme inhibitor or -blocker for intensified hypertension control; and pravastatin for reduction of serum cholesterol level. Main Outcome Measures  Cost per quality-adjusted life-year (QALY) gained. Costs (in 1997 US dollars) and QALYs were discounted at a 3% annual rate. Results  The incremental cost-effectiveness ratio for intensive glycemic control is $41 384 per QALY; this ratio increased with age at diagnosis from $9614 per QALY for patients aged 25 to 34 years to $2.1 million for patients aged 85 to 94 years. For intensified hypertension control the cost-effectiveness ratio is -$1959 per QALY. The cost-effectiveness ratio for reduction in serum cholesterol level is $51 889 per QALY; this ratio varied by age at diagnosis and is lowest for patients diagnosed between the ages of 45 and 84 years. Conclusions  Intensified hypertension control reduces costs and improves health outcomes relative to moderate hypertension control. Intensive glycemic control and reduction in serum cholesterol level increase costs and improve health outcomes. The cost-effectiveness ratios for these 2 interventions are comparable with those of several other frequently adopted health care interventions.